Brief: Celyad Highlights Safety And Clinical Activity Of CYAD-101

Celyad Oncology SA

11/11/2019 06:13

Nov 11 (Reuters) - Celyad SA  CYAD.BR :
    * CELYAD HIGHLIGHTS SAFETY AND CLINICAL ACTIVITY OF
CYAD-101, A
FIRST-IN-CLASS, NON-GENE EDITED ALLOGENEIC CAR-T THERAPY FOR
MCRC, FROM  SITC 34TH ANNUAL MEETING
    * EXPANSION SEGMENT OF TRIAL ANTICIPATED TO BEGIN IN
MID-2020
    * BEST OVERALL RESPONSE IN ALLOSHRINK TRIAL IN REFRACTORY
METASTATIC COLORECTAL CANCER (MCRC) PATIENTS WHO HAD PREVIOUSLY
RECEIVED PRIOR OXALIPLATIN-BASED CHEMOTHERAPY
    * ENROLLMENT COMPLETED IN DOSE-ESCALATION SEGMENT OF
ALLOSHRINK
TRIAL WITH ADDITIONAL RESULTS EXPECTED IN FIRST HALF 2020
    * RESULTS FROM ONGOING, DOSE-ESCALATION ALLOSHRINK PHASE 1
TRIAL
DEMONSTRATE ABSENCE OF GRAFT-VERSUS-HOST DISEASE

Source text for Eikon:  ID:nGNX3tWk22 
Further company coverage:  CYAD.BR 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7785110;))